Dreamit Ventures’ accelerator has ditched the demo day, according to Chief Innovation Officer Steve Barsh. That’s not the only change the early-stage venture firm and accelerator has made of late.
The Maryland Technology Development Corp. is giving a total of $800,000 in investments to four biotech companies.
Each of the firms will receive a $200,000 grant through TEDCO’s Life Science Investment Fund. The fund was created to help give startup companies in life sciences fields a chance to have their technology validated by the U.S. Food and Drug Administration, and to help further develop the product.
Maryland may have seen investments from venture capitalists decrease in the second quarter, but a director at PwC says he is not concerned.
Medical science and bio technology has given second chances to so many lives, especially in the form of prostheses. Gone are the days where your life was over if you lost a limb or two. So to honour this achievement in human endurance and scientific method, we’ve made a list of ten body parts that could theoretically be replaced if lost.
Rumors of staff cuts from AstraZeneca’s ($AZN) MedImmune biologics arm are part of previously stated changes and a deeper focus (and a larger cash pile) for its oncology research.
Rumors have been growing that AZ was axing staffers at MedImmune over the past week, but the Big Pharma tells FierceBiotech that this is part of the course originally announced back in its Q1 update in the spring.
Another month, another blockbuster deal in Boston-area real estate.
Alexandria Real Estate Equities has an agreement to buy the eight-acre One Kendall Square complex for $725 million, and it plans to add another building to the nine-building campus of office and lab space, the company disclosed in a securities filing. The complex includes the Kendall Square Cinema and several restaurants in addition to the office buildings.
VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, announced that it won a $2.4 million Peer Reviewed Medical Research Program Technology/Therapeutic Development Award #W81XWH-16-1-0330 from the Department of Defense Peer Reviewed Medical Research Program to advance its malaria vaccine development program.
CHINA is on the cusp of an innovation revolution, with the country’s biomedical and healthcare sectors making great leaps in the last decade. The achievements are quite visible: the exponential growth of publication of academic articles, patent filings, international exchanges, globalisation of new drug R&D activities, and accessibility of new drug R&D technology capability platforms from both China and overseas, just to name a few.
Virginia Tech is talking to large pharmaceutical firms about cooperating with the university on research projects and opening offices inside Roanoke’s new health care innovation district.
Michael Friedlander, founder of Virginia Tech Carilion Research Institute and a driving force behind the city’s growing health care industry, said that sort of partnership is only a concept, but affirmed that conversations are underway.
Advanced biomaterials joined with small molecules and biologics can allow regeneration and restoration functions of human tissues and organs.
The scope of application has extended far beyond acute injuries, chronic diseases and congenital malformations into therapeutics, research and difficult-to-treat diseases.